GuangYuYuan Chinese Herbal Medicine Co Ltd

GuangYuYuan Chinese Herbal Medicine Co Ltd maintains a strong liquidity position, with a current ratio of 2.15, indicating the company can cover its short-term liabilities with its short-term assets. However, the company has a negative net cash position after subtracting total debt, which introduces a medium liquidity risk. The company's price-to-book ratio of 4.49 and price-to-tangible-book ratio of 4.49 suggest that the market is valuing the company's equity at a premium relative to its book value. The company's profitability metrics show a return on equity (ROE) of 3.86% and a return on assets (ROA) of 2.59%, which are below the typical thresholds for high-performing pharmaceutical firms. These figures indicate that the company is generating relatively modest returns on its equity and asset base. The net income of 63.04 million CNY and operating income of 111.22 million CNY reflect a narrow profit margin, which may limit the company's ability to reinvest in growth or withstand market volatility. Geographically and segment-wise, the company's revenue is concentrated in a single business line, as disclosed in its financials. There is no indication of geographic diversification in the provided data, which could expose the company to regional economic or regulatory risks. The lack of segmental breakdown in the input data prevents a more granular analysis of revenue concentration. The company's growth trajectory appears modest, with no specific numeric deltas provided for the current or next fiscal year. The capital expenditure of -6.24 million CNY suggests a reduction in investment in physical assets, which may indicate a focus on cost control or a shift in strategic priorities. The company's free cash flow of 103.70 million CNY provides some flexibility for dividends or debt reduction, but the low net income limits the scope for aggressive reinvestment. The risk assessment highlights a medium liquidity risk and a low dilution risk. The company's debt-to-equity ratio of 0.04 indicates a conservative capital structure with minimal leverage. However, the negative net cash position after subtracting total debt raises concerns about the company's ability to meet short-term obligations without external financing. The low dilution risk is supported by the absence of significant share issuance activity in the provided data. Recent events, such as analyst estimates and financial filings, indicate a stable but unremarkable performance. The last actual EPS was 0.07 CNY, which is relatively low and may not meet investor expectations for growth in the pharmaceutical sector. The company's market price of 14.96 CNY and a price-to-earnings ratio of 116.15 suggest that the stock is trading at a high multiple, which may reflect investor optimism or a lack of near-term earnings growth.